Evidence map›Paper›PMID 20861839›Full record

ArticleNature2010

Crystal structure of the human symplekin-Ssu72-CTD phosphopeptide complex.

Kehui Xiang, Takashi Nagaike, Song Xiang, Turgay Kilic, Maia M Beh, James L Manley, Liang Tong

Abstract read
In one paragraph

Article in Nature, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 115 papers.

0numbers the graph read from it
0cells of the map it votes in
115citing papers in PubMed
6.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

115 citing papers in PubMed, 170 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review

55 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 2 countries.

Kehui XiangDepartment of Biological Sciences, Columbia University, New York, New York 10027, USA.
Takashi Nagaike
Song Xiang
Turgay Kilic
Maia M Beh
James L Manley
Liang Tong
Columbia University · US

Funding

Case Center for Synchrotron BiosciencesP30EB009998 · NIBIB · CASE WESTERN RESERVE UNIVERSITY · PI CHANCE, MARK R · 2009 to 2018
$8.4M
MRNA SYTHESIS IN ANIMAL CELLS--3END FORMATIONR01GM028983 · NIGMS · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI MANLEY, JAMES L. · 1985 to 2014
$6.4M
Structural biology of pre-mRNA 3'-end processingR01GM077175 · NIGMS · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI TONG, LIANG · 2007 to 2015
$2.8M
NIBIB NIH HHS P30 EB009998NIGMS NIH HHS GM028983NIGMS NIH HHS GM077175NIGMS NIH HHS R01 GM028983NIGMS NIH HHS R01 GM077175
6 · The paper itself

Abstract

Symplekin (Pta1 in yeast) is a scaffold in the large protein complex that is required for 3'-end cleavage and polyadenylation of eukaryotic messenger RNA precursors (pre-mRNAs); it also participates in transcription initiation and termination by RNA polymerase II (Pol II). Symplekin mediates interactions between many different proteins in this machinery, although the molecular basis for its function is not known. Here we report the crystal structure at 2.4 Å resolution of the amino-terminal domain (residues 30-340) of human symplekin in a ternary complex with the Pol II carboxy-terminal domain (CTD) Ser 5 phosphatase Ssu72 (refs 7, 10-17) and a CTD Ser 5 phosphopeptide. The N-terminal domain of symplekin has the ARM or HEAT fold, with seven pairs of antiparallel α-helices arranged in the shape of an arc. The structure of Ssu72 has some similarity to that of low-molecular-mass phosphotyrosine protein phosphatase, although Ssu72 has a unique active-site landscape as well as extra structural features at the C terminus that are important for interaction with symplekin. Ssu72 is bound to the concave face of symplekin, and engineered mutations in this interface can abolish interactions between the two proteins. The CTD peptide is bound in the active site of Ssu72, with the pSer 5-Pro 6 peptide bond in the cis configuration, which contrasts with all other known CTD peptide conformations. Although the active site of Ssu72 is about 25 Å from the interface with symplekin, we found that the symplekin N-terminal domain stimulates Ssu72 CTD phosphatase activity in vitro. Furthermore, the N-terminal domain of symplekin inhibits polyadenylation in vitro, but only when coupled to transcription. Because catalytically active Ssu72 overcomes this inhibition, our results show a role for mammalian Ssu72 in transcription-coupled pre-mRNA 3'-end processing.

Indexed as

AnimalsBinding SitesCarrier ProteinsCatalytic DomainCrystallography, X-RayDrosophila ProteinsHumansModels, MolecularmRNA Cleavage and Polyadenylation FactorsNuclear ProteinsPhosphopeptidesPhosphoprotein PhosphatasesPolyadenylationProtein BindingProtein Structure, SecondaryProtein Structure, Tertiarycarboxy-terminal domain phosphataseCarrier ProteinsDrosophila ProteinsmRNA Cleavage and Polyadenylation FactorsNuclear ProteinsPhosphopeptidesPhosphoprotein PhosphatasesPTA1 protein, S cerevisiaeRNA Polymerase IISaccharomyces cerevisiae ProteinsSSU72 protein, humanSYMPK protein, humanSym protein, Drosophila

Identifiers

PMID20861839
PMCPMC3038789
OpenAlexW2026111998

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.